Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI) (Journal of Psychopharmacology 21, 2, DOI: 10.1177/0269881107066855);Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)

Journal of Psychopharmacology

Volumn 21, Issue 2, 2007, Pages 171-178

  Dunbar, Geoffrey C ^a   Inglis, Fraser ^b   Kuchibhatla, Ramana ^a   Sharma, Tonmoy ^c   Tomlinson, Mark ^d   Wamsley, James ^a  

^a TARGACEPT INC   (United States)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^c NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^d SK10 4TJ   (United Kingdom)

Author keywords

Age associated memory impairment; Cognition; Ispronicline; Neuronal nicotinic acetylcholine receptor

Indexed keywords

ISPRONICLINE; PLACEBO;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD CHEMISTRY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEMATOLOGICAL PARAMETERS; HEMATOLOGY; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VITAL SIGN;

EID: 33847137816     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108096190     Document Type: Erratum

References (16)

1. Buccafusco J, Letchworth S, Bencherif M, Lippiello P M (2005) Long lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends in Pharmacological Research, 26: 352 - 360
2. Court J A, Lloyd S, Johnson M, Griffiths M, Birdsall N J, Piggott M A, Oakley A E, Ince P G, Perry E K, Perry R H (1997) Nicotinic and muscarinic cholinergic receptor binding in the human hippocampal formation during development and aging. Developmental Brain Research 101: 93 - 105
3. Crook T, Bartus T, Ferris S, Whitehouse P, Cohen G, Gershon S (1986) Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of a National Institute of Mental Health work group. Developmental Neurobiology 2: 261 - 276
4. Dunbar G C (2005) Ispronicline: safety, tolerability, pharmacokinetic and Pharmaco EEG changes in volunteer studies. In Fisher A, Hanin I, Memo M, Stocchi F (eds). New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2005. International Proceedings, Medimondi, Bologna, Italy, pp. 235 - 241
5. Dunbar G C, Kuchibhatla R V (2006) Cognitive enhancement in man with ispronidine, a nicotinic partial agonist. Journal Molecular Neuro science (In press)
6. Fratiglioni L, Wang H X (2000) Smoking and Parkinson's and Alzheimer's disease: review of the epidemiology studies. Behavioral Brain Research 113: 117 - 120
7. Gatto G J, Andrees Bohme G, Caldwell W S, Letchworth S R, Traina V M, Obinu M C, Laville M, Reibaud M, Pradier L, Dunbar G, Bencherif M (2004) TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant neuroprotective and long lasting cognitive effects. CNS Drugs Review 10: 147 - 166
8. Levin E D (1992) Nicotinic systems and cognitive function. Special issue: nicotine. Psychopharmacology, 108: 417 - 431
9. Levin E D, Rezvani A H (2000) Development of nicotinic drug therapy for cognitive disorders. European Journal of Pharmacology, 393: 141 - 146
10. Min S K, Moon I W, Ko R W, Shin H S (2001) Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers. Psychopharmacology 159: 83 - 88
11. Perry E K, Perry R H, Gibson P, Blessed G, Tomlinson B (1977) A cholinergic connection between normal aging and senile dementia in human hippocampus. Neuroscience Letters 6: 85 - 89
12. Warburton D M (1990) Psychopharmacological aspects of nicotine. In Wonnacot S, Russell M A H, Stolerman I P, (eds). Nicotine Psychopharmacology: Molecular, Cellular and Behavioral Aspects. Oxford University Press, Oxford, pp. 77 - 111
13. Wechsler D (1987) The Wechsler Memory Scale - Revised. Harcourt, Sidcup Wesnes K A (2000) The value of assessing cognitive function in drug development. Dialogues in Clinical Neuroscienc, 2: 183 - 202
14. Wesnes K A, Ward T, McGinty A, Petrino O (2000) The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology 152: 353 - 361
15. White H K, Levin E D (1999) Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 143: 158 - 165
16. White H K, Levin E D (2004) Chronic transdermal nicotine patch treatment: effects on cognitive performance in age-associated memory impairment. Psychopharmacology 171: 465 - 471